Option chain shows key data for Sensei Biotherapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Sensei Biotherapeutics.

Sensei Biotherapeutics (NASDAQ:SNSE) Stock, Option Chain

Sensei Biotherapeutics

Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing highly selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101, SNS-102, SNS-103, SNS-20.

Apple, Nio, CVS Health, Stellantis, Tesla: Why These 5 Stocks Are On Investors' Radars Today

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ADXN

ATNI

BIVI

BOOM

ENSC

GNPX

ALPS ETF Trusthen & Steers Global Realty Majors ETF

INAB

IRTC

KSCP

MEDP

MKTW

NTBL

SNSE

TCBP

Why iRhythm Technologies Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket

Intraday Update

AKAN

AKTS

ASTI

ATGL

BIOR

BNED

BSFC

BTTR

CADL

DAVA

DECK

GNLX

GYRE

HLTH

IMCR

INTU

ISSC

KRON

LILM

LUCY

LUXH

MGNI

MRNO

MRUS

NCPL

NTES

OKLO

ONMD

PEGY

RDZN

ROST

SMFL

SMMT

SVMH

SWIN

TLSI

VSTM

WDAY

WORX

XCUR

ZCAR

Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Wall Street

Earnings

Eurozone

Commodities

Dow Surges 50 Points; US Durable Goods Orders Increase In April

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics Inc

On December 20, 2024, Superior Group of Companies, Inc. (the "Company") entered into a 10b5-1 trading plan (the "Plan") for the purpose of repurchasing up to $2,580,000.00 in shares of the Company's outstanding common stock (the "Repurchase Limit") in accordance with the previously-announced share repurchase program authorized by the Company's Board of Directors on August 9, 2024. The Plan is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. The Plan allows the Company to repurchase shares up to the Repurchase Limit commencing December 20, 2024 and ending on the earlier of the date on which the Repurchase Limit is reached, March 13, 2025, or other events specified in the Plan. Repurchases of common stock under the Plan will be administered through an independent broker and are subject to certain price, market, volume and timing constraints specified in the Plan.

Buybacks

Superior Group Announces Trading Plan For $2.58M Stock Buyback, Effective December 20 To March 13, 2025

WIIM

TRAW

Traws Pharma shares are trading higher after they announced progress in the development of Tivoxavir Marboxi.

Our plants around the world are regularly inspected by health authorities to ensure compliance with the various markets we serve. Following an inspection by the U.S. FDA at our oral finished dose manufacturing facility in Indore, India earlier this year, the Agency has issued a Warning Letter, and an Import Alert related to this facility.
The Import Alert affects 11 actively distributed products that will no longer be accepted into the U.S. until the Warning Letter is lifted. It makes exceptions, subject to certain conditions, for four products based on shortage concerns. There could be the potential for additional exceptions based on further discussions with the Agency.
Following the substance of FDA's original inspection observations, we immediately implemented a comprehensive remediation plan at the site. The necessary corrective and preventive actions are well underway, including but not limited to related personnel actions. Additionally, we have engaged independent third-party subject matter experts to support the remediation plan.
We have been in regular communication with FDA during this process and will continue to work to ensure that the Agency is satisfied with the steps we have taken to resolve all the points raised. Our response to the Warning Letter and Import Alert will be submitted within the required time periods.
At this time, we do not anticipate these actions impacting our current 2024 financial guidance ranges. We will incorporate&nbsp;potential future financial impact&nbsp;in our 2025 guidance ranges when we provide these in early 2025.
We take very seriously our continued and comprehensive oversight of our entire manufacturing network. Patient safety remains our primary and unwavering focus. We will work closely with our customers to mitigate any possible supply disruptions and meet the needs of the patients we serve.

Global

VTRS

Viatris Issues Statement Regarding Receipt Of Warning Letter And Import Alert For Indore, India Facility; The Import Alert Affects 11 Actively Distributed Products That Will No Longer Be Accepted Into The U.S. Until The Warning Letter Is Lifted

Citigroup analyst Gabriel Barra reinstates Cosan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSAN#NYSE">CSAN</a>) with a Buy and announces $19 price target.

Price Target

Initiation

Analyst Ratings

CSAN

Citigroup Reinstates Buy on Cosan, Announces $19 Price Target

Biotech

General

ALNY

GIVLAARI Gains Nationwide Reimbursement In Canada For Treating Acute Hepatic Porphyria

PLYA

Playa Hotels & Resorts shares are trading higher after Hyatt Hotels disclosed it executed an exclusivity agreement to potentially acquire the company.

AILE

Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times

OMIC

Trading Halt: Halted at 8:25:00 a.m. ET - Trading Halt: Halt News Pending

Intuitive Machines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>, LUNRW))) ("Intuitive Machines" or the "Company"), a space exploration, infrastructure, and services company, has secured additional contracts from NASA's Near Space Network ("NSN") for Direct-to-Earth ("DTE") services. These contracts further position Intuitive Machines as a vital partner in supporting NASA's missions to the Moon, and beyond.
DTE communication and navigation services are critical for enabling missions to exit Earth's orbit, reach lunar destinations, and explore deep space. The new contract awards include:
<ul>
<li>Subcategory 1.2: DTE Geostationary ("GEO") to Cislunar DTE Services, offering enhanced data transmission capabilities and autonomous operations.</li>
<li>Subcategory 1.3: xCislunar DTE Services, addressing mission needs for highly elliptical orbits and deep space operations.</li>
</ul>
Both contracts are firm-fixed-price, indefinite-delivery/indefinite-quantity task orders designed to bolster NASA's Lunar Exploration Ground Segment. These awards add capacity to alleviate demand on the Deep Space Network and support unique mission requirements.

Contracts

LUNR

Intuitive Machines Has Secured Additional Contracts From Nasa's Near Space Network For Direct-to-Earth Services

Ocean Power Technologies, Inc. (NYSE:<a href="https://www.benzinga.com/stock/OPTT#NYSE">OPTT</a>) ("OPT" or the "Company"), a leader in innovative and cost-effective low-carbon marine power, data, and service solutions, today announced it has finalized the main assembly of the previously announced PowerBuoy&#xAE; for Naval Postgraduate School. The full system, which includes installing AT&amp;T&#xAE; 5G technology and integrating advanced subsea sensors into a PowerBuoy&#xAE; equipped with OPT's latest Merrows&#x2122; suite for AI capable seamless integration of Maritime Domain Awareness (MDA) across platforms, is now being readied for shipment ready for deployment in early 2025 alongside the Technology Showcase NPS is hosting in January. Once deployed, the PowerBuoy&#xAE; will provide continuous, autonomous monitoring and data collection capabilities in one of the world's most strategically significant maritime environments. This is another step forward in executing the Company's robust strategic plan.

OPTT

Ocean Power Technologies Readies Shipment Of AI Capable Merrows PowerBuoy For Naval Postgraduate School

Meeting Minimum Bid Price And Stockholders' Equity Requirements; Common Stock To Continue Trading On Nasdaq Capital Market

Ensysce Biosciences Regains Full Nasdaq Compliance

Canaccord Genuity analyst Austin Moeller maintains Vertical Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVTL#NYSE">EVTL</a>) with a Buy and maintains $16 price target.

EVTL

Canaccord Genuity Maintains Buy on Vertical Aerospace, Maintains $16 Price Target

WISA

WiSA Technologies Stockholders Approve Acquisition Of Data Vault Assets Valued At $266M-$501M; Deal Includes 40M Shares And $10M Note, Transforming Into Datavault Inc. With Blockchain, AI, And Web 3.0 Solutions Across Multiple Industries

New Fortress Energy shares are trading higher after Stifel maintained a Buy rating and raised its price target from $16 to $17.

iHeartMedia, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IHRT#NASDAQ">IHRT</a>) ("iHeartMedia" or the "Company") today announced the successful completion of its previously announced comprehensive exchange transactions of iHeartCommunications, Inc.'s ("iHeartCommunications") outstanding 6.375% Senior Secured Notes due 2026 (the "2026 Secured Notes"), 5.25% Senior Secured Notes due 2027 (the "2027 Secured Notes"), 4.75% Senior Secured Notes due 2028 (the "2028 Secured Notes"), 8.375% Senior Notes due 2027 (the "Unsecured Notes") and senior secured term loans due 2026 (the "Existing Term Loans") (collectively, the "Existing Debt") for new 9.125% Senior Secured First Lien Notes due 2029, 7.750% Senior Secured First Lien Notes due 2030, 7.000% Senior Secured First Lien Notes due 2031, 10.875% Senior Secured Second Lien Notes due 2030 and senior secured first lien term loans due 2029, respectively, in each case issued by iHeartCommunications (collectively, the "Exchange Offers").
Approximately $4.8 billion (or 92.2%) of the aggregate principal amount of the Existing Debt participated in the Exchange Offers, which expired at 9:00 a.m., New York City time, on December 18, 2024 (the "Expiration Time").

IHRT

iHeartMedia Completes Debt Exchange Offers, Reduces Debt by $440M, Extends Maturities by 3 Years, $4.8B (92.2%) of Existing Debt Participated, Strengthens Capital Structure with New Senior Secured Notes and Loans Due 2029-2031

<a href="https://www.bloomberg.com/news/articles/2024-12-23/metlife-is-said-to-near-deal-to-buy-hk-tycoon-li-s-pinebridge?embedded-checkout=true" title="https://www.bloomberg.com/news/articles/2024-12-23/metlife-is-said-to-near-deal-to-buy-hk-tycoon-li-s-pinebridge?embedded-checkout=true">https://www.bloomberg.com/news/articles/2024-12-23/metlife-is-said-to-near-deal-to-buy-hk-tycoon-li-s-pinebridge?embedded-checkout=true</a>

MetLife Nearing $1.4B Deal To Acquire PineBridge Excluding China Assets; Announcement Expected Monday, Valuing $100B AUM Outside China At $1.3B-$1.4B

Sky Harbour Group Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKYH#NYSE">SKYH</a>, SKYH WS))) (&quot;SHG&quot; or the &quot;Company&quot;), an aviation infrastructure company building the first nationwide network of Home-Basing campuses for business aircraft, announced it has completed the second closing of its previously announced equity raise. The Company issued an additional 3,955,790 PIPE shares of its Class A Common Stock in connection with the exercise of all the rights to purchase additional shares provided to PIPE investors who participated in the first closing for net proceeds of approximately $37.6 million, at a sale price of $9.50 per share. Aggregate proceeds from both closings were approximately $75.2 million, representing the full capacity of the equity raise.

SKYH

Sky Harbour Completes Second Closing Of Equity Raise, Issuing 3.96M PIPE Shares At $9.50 Each For $37.6M; Total Proceeds From Both Closings Reach $75.2M

Elon Musk&#8217;s artificial intelligence company, xAI, is testing a standalone Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) iOS app&nbsp;for its chatbot, Grok.
Grok was now available only to users of Musk-owned X (formerly Twitter Inc).
The app can access real-time data from the web and X and offers generative AI features like rewriting text&nbsp;and generating images&nbsp;<a target="_blank" href="https://apps.apple.com/au/app/grok/id6670324846" rel="noreferrer noopener">from text prompts</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/24/12/42613368/broadcom-expects-decade-long-ai-chip-boom-as-big-tech-invest-billions" rel="noreferrer noopener">Broadcom Expects Decade-Long AI Chip Boom as Big Tech Invest Billions</a>
xAI is also preparing a site, Grok.com, to make the chatbot accessible on the web, TechCrunch <a target="_blank" href="https://techcrunch.com/2024/12/22/xai-is-testing-a-standalone-ios-app-for-its-grok-chatbot/" rel="noreferrer noopener">reports</a>.
Grok was previously available only to X&#8217;s paying subscribers. In November, the company&nbsp;started testing a free chatbot version and rolled it out to&nbsp;all users earlier this month.
The company&#8217;s chatbot image generator model allows users to create images using pictures of public figures and copyrighted material.
xAI has reportedly reached a <a target="_blank" href="https://www.benzinga.com/startups/24/11/42235738/in-just-16-months-elon-musk-achieved-with-xai-what-took-openai-nearly-nine-years-to-accomplish" rel="noreferrer noopener">$50 billion valuation</a> just 16 months after its July 2023 founding, surpassing the billionaire&#8217;s spending on acquiring Twitter.
OpenAI, one of the most recognized names in artificial intelligence, took over nine years to reach its current valuation of $157 billion.
Reportedly, xAI is rapidly gaining momentum in the competitive AI market, now valued higher than rivals like Anthropic, worth $19 billion, and Perplexity, valued at $2.8 billion.
xAI achieved significant milestones by securing $5 billion in its latest funding round to acquire 100,000 Nvidia chips.
These chips will drive the Memphis supercomputer, a facility built to advance the company&#8217;s AI capabilities and bolster Tesla&#8217;s Full Self-Driving (FSD) technology.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42561240/salesforces-ai-powered-agentforce-20-spurs-analyst-upgrades-and-growth-optimism" target="_blank" rel="noreferrer noopener">Wall Street Analysts Are Bullish On Salesforce&#8217;s AI Vision &#8211; Here&#8217;s Why</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

Media

AAPL

AMZN

MSFT

NVDA

Elon Musk's xAI To Expand With New Chatbot App

Fly-E Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLYE#NASDAQ">FLYE</a>) ("Fly-E" or the "Company"), an electric vehicle company engaged in designing, installing, selling, and renting smart electric motorcycles, electric bikes, electric scooters, and related accessories, today announced that its flagship e-bike model, the Fly-11 PRO, has been officially selected by the New York City Department of Transportation ("NYC DOT") as the official e-bike for the E-Bike Trade-In Program (the "Program"). NYC DOT expects to distribute approximately 400 e-bikes during the pilot period.

FLYE

Fly-E Group Selected As The Official E-Bike Provider For NYC DOT's Trade-In Program

Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) and Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) show strong fundamentals, but the trader community remains hesitant about their potential to outperform <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42535162/hyperliquid-emerges-as-ethereum-solana-rival-heres-how-high-hype-could-go">other trending cryptocurrencies</a>.
What Happened: Shibburn data shows 6.02 million SHIB tokens burned in the past 24 hours, driving the burn rate up by 661.7%. 
Key transactions included burns of 3.5 million and 2.3 million SHIB, signaling increased on-chain activity.
Shibarium&#8217;s December 2024 update <a href="https://x.com/Shibizens/status/1870792229461074044">highlights</a> the network undergoing a mainnet upgrade.
Among the milestones achieved, it crossed 688 million transactions, peaked to all time high in new total value locked and a maintained 4 million daily transactions volume.
The recent integration with Chainlink is expected to enhance cross-chain functionality, boost on-chain activity and accelerate SHIB burns.
On the Dogecoin front, crypto analyst Ali Martinez highlighted historical patterns where DOGE experienced parabolic rallies after significant retracements. 
For example, DOGE surged thousands of percent following pullbacks in 2017 and 2021. 
In 2024, after a 440% rally and 46% retracement, another explosive move <a href="https://x.com/ali_charts/status/1871097660888813871">could</a> be on the horizon.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42626582/dogecoin-shiba-inu-absent-from-2024s-top-performing-meme-coins-heres-who-made-the-cut">Dogecoin, Shiba Inu Absent From 2024&#8217;s Top-Performing Meme Coins: Here&#8217;s Who Made The Cut</a>
Trader Notes: Altcoin Sherpa sees meme coins performing well but doubts their ability to outperform other crypto assets in the latter half of the market cycle. 
While Dogecoin's brand recognition and Elon Musk's involvement make it unique, Sherpa argues that smaller-cap meme tokens like Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>) and Dogwifhat (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">WIF</a>) might outpace larger-cap memes.
He also <a href="https://x.com/AltcoinSherpa/status/1870504266781302822">suggests</a> big-cap meme coins will likely remain dependent on broader market movements, with a significant rally in Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) potentially lifting memes.
Sherpa concluded that while recognizable tokens like Shiba Inu, Floki (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">FLOKI</a>), and Dogwifhat will perform decently, they're unlikely to outperform top utility tokens like Aave (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/aave/usd">AAVE</a>), Hyperliquid (CRYPTO: HYPE) and Ethena (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">ENA</a>), or trending crypto sectors such as AI-driven projects.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42514226/shiba-inu-burn-rate-surges-3609-as-dogecoin-whales-move-5-8-billion-doge-what-is-going-on">Shiba Inu Burn Rate Surges 3,609% As Dogecoin Whales Move 5.8 Billion DOGE: What Is Going On?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$AAVE

$DOGE

$ENA

$ETH

$FLOKI

$PEPE

$SHIB

$WIF

Dogecoin, Shiba Inu Could Underperform Stronger Cryptos, Trader Warns: Here's Why

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sensei Biotherapeutics (SNSE – Research Report) an...

Analysts Offer Insights on Healthcare Companies: Sensei Biotherapeutics (SNSE) and Omeros (OMER)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sensei Biotherapeutics (SNSE – Research Report) and ...

Analysts Are Bullish on These Healthcare Stocks: Sensei Biotherapeutics (SNSE), Viking Therapeutics (VKTX)

Sensei Biotherapeutics (SNSE) has shared an announcement. Dr. Jessie English has announced her resignation from the Board of Directors at Sensei Bi...

Dr. Jessie English Resigns from Sensei Biotherapeutics Board

Sensei Biotherapeutics GAAP EPS of -$0.28

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Sensei Biotherapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/snse-stock-quote/">SNSE</a>) just reported results for the second quarter of 2024.<ul><li>Sensei Biotherapeutics reported earnings per share of -28 cents. This was above the analyst estimate for EPS of -29 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/snse-stock-earnings-sensei-biotherapeutics-for-q2-of-2024/">SNSE Stock Earnings: Sensei Biotherapeutics Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

SNSE Stock Earnings: Sensei Biotherapeutics Beats EPS for Q2 2024

Sensei Biotherapeutics (SNSE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Edward White ...

Buy Rating Affirmed for Sensei Biotherapeutics on Strong Financials and Promising Drug Trials

Sensei Biotherapeutics ( ($SNSE) ) just unveiled an announcement. Sensei Biotherapeutics, Inc. recently appointed Josiah Craver as their new princi...

Sensei Biotherapeutics Appoints New Financial Chief

"The third quarter of 2024 saw significant progress in advancing patient enrollment in the dose expansion portion of the Phase 1 study for SNS-101 ...

Sensei Biotherapeutics reports Q3 EPS (29c), consensus (32c)

Sensei Biotherapeutics GAAP EPS of -$0.29

Sensei Biotherapeutics, Inc. ( ($SNSE) ) has released its Q3 earnings. Here is a breakdown of the information Sensei Biotherapeutics, Inc. presente...

Sensei Biotherapeutics Q3 2024 Results and Strategic Moves

OMER

VKTX

Health Care

Press Releases

Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting

Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101

Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference

Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Sensei Biotherapeutics to Present at Upcoming Conferences

Sensei Biotherapeutics to Present Preclinical Data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference

Sensei Biotherapeutics to Present at Two Upcoming Scientific Conferences

Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Sensei Biotherapeutics to Participate in Citi's 2024 Global Healthcare Conference

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

Addex Therapeutics Ltd - American Depositary Shares

Addex Therapeutics

AIM ImmunoTech

Apollomics Inc. - Class A Ordinary Shares

Apollomics

BioCardia

Brainstorm Cell Therapeutics Inc. - Common Stock

Brainstorm Cell

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Cyclerion Therapeutics, Inc. - Common Stock

Cyclerion Therapeutics

Ensysce Biosciences

Comments

Sensei Biotherapeutics

Sensei Biotherapeutics (SNSE) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga